Durgical
EN
Open the app

Treating venous thromboembolism: how long, and in cancer and pregnancy

  • Treatment and support

After a clot in the leg or lung, the big decision is how long to keep the blood thinner. The cause of the clot answers it.

Updated

What it is

Treatment of venous thromboembolism (VTE) has three phases: initial treatment in the first days, the main course of at least 3 months, and extended treatment for patients whose risk of another clot stays high. The drug is chosen by the patient (kidneys, cancer, pregnancy, APS, interacting drugs); the length is set by why the clot happened. Massive PE with shock needs reperfusion (thrombolysis or a procedure), and a vena cava filter is reserved for acute clots when anticoagulation is impossible.

What to know

  • Every VTE gets at least 3 months of anticoagulation.
  • Provoked by a major transient factor (surgery, trauma, immobilisation): stop at 3 months; recurrence is low.
  • Unprovoked, or a persistent risk factor: consider extended treatment if bleeding risk is low, with yearly review.
  • Active cancer: an oral Xa inhibitor or low-molecular-weight heparin, for at least 6 months and while the cancer is active; heparin is often preferred in gut or urinary cancers with high bleeding risk.
  • Pregnancy: low-molecular-weight heparin for the rest of the pregnancy and at least 6 weeks after delivery, for a total of at least 3 months; warfarin and DOACs are avoided in pregnancy.
  • DOACs are first choice for most other patients; dabigatran and edoxaban need a few days of heparin first, apixaban and rivaroxaban do not.

How it is done (and why)

  1. Confirm the clot and check for shock or right heart strain: high-risk PE goes to reperfusion.
  2. Start anticoagulation at once unless there is active bleeding.
  3. Decide where: many low-risk PE and most DVT patients can be treated at home with follow-up.
  4. Classify the clot: provoked by a major or minor transient factor, persistent risk, or unprovoked.
  5. Choose the drug by kidney function, cancer, pregnancy, APS, drug interactions and access to monitoring.
  6. Review at 3 months: stop, or continue with a yearly check of bleeding risk, kidney function and wishes.
  7. Encourage early walking; compression stockings can ease symptoms but are not used routinely to prevent the post-thrombotic syndrome.

Which drug, how long

SituationUsual choiceHow long
Provoked by surgery or traumaDOAC3 months, then stop
UnprovokedDOACAt least 3 months; consider extended if bleeding risk is low
Active cancerOral Xa inhibitor or low-molecular-weight heparinAt least 6 months and while cancer is active
PregnancyLow-molecular-weight heparinRest of pregnancy plus at least 6 weeks postpartum (minimum 3 months)
Antiphospholipid syndromeWarfarinUsually long term
Isolated calf (distal) DVTAnticoagulate, or repeat ultrasound if low risk3 months if treated

Risks and precautions

  • Major bleeding risk rises with age, previous bleeding, kidney or liver disease, cancer, alcohol and antiplatelet use; it is weighed again at every review.
  • Warfarin and low-molecular-weight heparin are compatible with breastfeeding; DOACs are avoided while breastfeeding.
  • Low-molecular-weight heparin is paused before planned delivery to allow neuraxial anaesthesia; the timing is agreed with the anaesthesia team.
  • A vena cava filter does not treat the clot and raises later DVT risk; it should be retrieved once anticoagulation is possible.

Monitoring and next step

  • Before starting: count, PT, aPTT, creatinine and liver tests.
  • During treatment: kidney function and count at intervals; INR if on warfarin; anti-Xa only in special cases (pregnancy, kidney failure, extreme weight).
  • Unprovoked VTE: careful history, examination and age-appropriate cancer screening; extensive scans have not shown benefit.
  • At 3 months: reassess symptoms, bleeding, the cause and the case for extended treatment.
  • Persistent breathlessness months after a PE: echocardiography to look for chronic thromboembolic pulmonary hypertension.

Common traps

  • Giving every patient a fixed 6 months whatever the cause: provoked clots need 3 months, and unprovoked clots may need longer.
  • Stopping anticoagulation in a patient with active cancer at 3 months: a 3-month course is too short while the cancer is active.
  • Using a DOAC in pregnancy or in high-risk APS: in neither setting is a DOAC the choice.
  • Placing a vena cava filter in a patient who can be anticoagulated, or forgetting to remove it: a filter is not for patients who can be anticoagulated, and one that is placed must later be removed.

Test yourself

Think of the answer, then tap the question to see it.

Why is a DVT after hip surgery usually treated for only 3 months, while an unprovoked DVT may be treated for longer?

Surgery is a trigger that has passed, so recurrence after stopping is low; with no trigger found, the cause persists and recurrence after stopping is higher.

Which anticoagulant is used for VTE in pregnancy, and for how long after delivery?

Low-molecular-weight heparin, continued for at least 6 weeks after delivery and for a total of at least 3 months.

Why may low-molecular-weight heparin be chosen over an oral Xa inhibitor in a patient with stomach cancer?

In trials some oral Xa inhibitors caused more bleeding in gut and urinary tract cancers; heparin also avoids absorption problems and some chemotherapy interactions.

When is a vena cava filter appropriate in acute VTE?

Only when anticoagulation cannot be given, for example active major bleeding; it should be removed once anticoagulation starts.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Deep Venous Thrombosis (StatPearls (NCBI Bookshelf), 2024); Acute Pulmonary Embolism (StatPearls (NCBI Bookshelf), 2024); Anticoagulant Therapy In Pregnancy (StatPearls (NCBI Bookshelf), 2026); About Venous Thromboembolism (Blood Clots) (Centers for Disease Control and Prevention (CDC), 2025).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.